SECsense Logo

Ultragenyx Pharmaceutical 8-K Report: Key Updates on February 13, 2025

$RARE
Form 8-K
Filed on: 2025-02-13
Source
Ultragenyx Pharmaceutical 8-K Report: Key Updates on February 13, 2025

Based on the provided excerpt from the financial report, here are the key pieces of information and insights extracted:

  1. Company Information:
  • Name: Ultragenyx Pharmaceutical Inc.
  • CIK: 0001515673 (Central Index Key used by the SEC).
  • Company Identifier: RARE (Common Stock, $0.001 par value).
  • Trading Symbol: RARE.
  • Exchange: NASDAQ.
  • Business Address: 60 Leveroni Court, Novato, CA 94949.
  • Phone Number: 415-483-8800.
  1. Filing Type:
  • Form Type: 8-K (a report used to notify investors of certain events that may be important to shareholders).
  1. Filing Date:
  • Date of Filing: February 13, 2025.
  1. Period Covered:
  • Start Date: February 13, 2025.
  • End Date: February 13, 2025.
  • This indicates that the report pertains to a specific event occurring on the same day it was filed.
  1. Regulatory Framework:
  • The report follows the XBRL (eXtensible Business Reporting Language) format which enhances the transparency and accessibility of financial data for analysis.

Insights:

  • The filing suggests that Ultragenyx Pharmaceutical Inc. is actively communicating significant corporate events or changes to its investors, as indicated by the 8-K filing.
  • The single-day coverage indicates that the event or information being reported is likely of immediate importance, warranting prompt disclosure.
  • The company operates in the pharmaceutical sector, which could imply regulatory scrutiny and a focus on compliance with FDA guidelines, especially pertinent to any recent developments in drug approvals or clinical trials.

This analysis provides a snapshot of the company's current reporting activity and its engagement with the market. Further details from the attached report would be needed to understand the specifics of the event disclosed in the 8-K.